Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZW) Cash & Equivalents (2021 - 2025)

Core Scientific (CORZW) has disclosed Cash & Equivalents for 5 consecutive years, with $311.4 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 62.76% to $311.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $311.4 million through Dec 2025, down 62.76% year-over-year, with the annual reading at $311.4 million for FY2025, 62.76% down from the prior year.
  • Cash & Equivalents hit $311.4 million in Q4 2025 for Core Scientific, down from $453.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $836.2 million in Q4 2024 to a low of $1.6 million in Q3 2021.
  • Historically, Cash & Equivalents has averaged $195.9 million across 5 years, with a median of $96.2 million in 2022.
  • Biggest YoY gain for Cash & Equivalents was 6186.29% in 2022; the steepest drop was 86.52% in 2022.
  • Year by year, Cash & Equivalents stood at $117.9 million in 2021, then plummeted by 86.52% to $15.9 million in 2022, then soared by 217.36% to $50.4 million in 2023, then skyrocketed by 1558.82% to $836.2 million in 2024, then tumbled by 62.76% to $311.4 million in 2025.
  • Business Quant data shows Cash & Equivalents for CORZW at $311.4 million in Q4 2025, $453.4 million in Q3 2025, and $581.3 million in Q2 2025.